In vivo knockdown of adipocyte erythropoietin receptor does not alter glucose or energy homeostasis

Endocrinology

Volumn 154, Issue 10, 2013, Pages 3652-3659

  Luk, Cynthia T ^a,b   Shi, Sally Yu ^a,b   Choi, Diana ^b   Cai, Erica P ^a,b   Schroer, Stephanie A ^a   Woo, Minna ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; GLUCOSE; INSULIN;

ADIPOCYTE; ADIPOSE TISSUE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CELL STRUCTURE; CONTROLLED STUDY; ENERGY BALANCE; ENERGY METABOLISM; FEMALE; GENE SILENCING; GLUCOSE METABOLISM; IN VIVO STUDY; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE, BROWN; ADIPOSE TISSUE, WHITE; ADIPOSITY; ADULT; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; ENERGY METABOLISM; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; INSULIN RESISTANCE; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; OBESITY; RECEPTORS, ERYTHROPOIETIN; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 84884687285     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1113     Document Type: Article

References (55)

1. Blüher M, Michael MD, Peroni OD, et al. Adipose tissue selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell. 2002;3:25-38. (Pubitemid 34778393)
2. He W, Barak Y, Hevener A, et al. Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA. 2003;100: 15712-15717. (Pubitemid 38021055)
3. Li P, Fan W, Xu J, et al. Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell. 2011;147:815-826.
4. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development. 1999;126:3597-3605. (Pubitemid 29419516)
5. Wittig I, Groner B. Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells. Curr Drug Targets Immune Endocr Metab Disord. 2005;5:449-463. (Pubitemid 41722386)
6. Umemura T, Umene K, Takahira H, et al. Hematopoietic growth factors (BPA and Epo) induce the expressions of c-myc and c-fos proto-oncogenes in normal human erythroid progenitors. Leuk Res. 1988;12:187-194.
7. Socolovsky M, Fallon AE, Wang S, Brugnara C, Lodish HF. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 1999;98:181-191.
8. Dumon S, Santos SC, Debierre-Grockiego F, et al. IL-3 dependent regulation of Bcl-xL gene expression by STAT5 in a bone marrow derived cell line. Oncogene. 1999;18:4191-4199. (Pubitemid 29377850)
9. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev Biol. 2004;276:101-110. (Pubitemid 39452849)
10. Sung HK, Doh KO, Son JE, et al. Adipose vascular endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell Metab. 2013;17:61-72.
11. Elias I, Franckhauser S, Ferré T, et al. Adipose tissue overexpression of vascular endothelial growth factor protects against diet-induced obesity and insulin resistance. Diabetes. 2012;61:1801-1813.
12. Sun K, Wernstedt Asterholm I, Kusminski CM, et al. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci USA. 2012;109:5874-5879.
13. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67.
14. Yu X, Shacka JJ, Suarez-Quian C, et al. Erythropoietin receptor signalling is required for normal brain development. Development. 2002;129:505-516. (Pubitemid 34863815)
15. Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA. 1995;92:3717-3720.
16. Depping R, Kawakami K, Ocker H, et al. Expression of the erythropoietin receptor in human heart. J Thorac Cardiovasc Surg. 2005; 130:877-878.
17. Fenjves ES, Ochoa MS, Cabrera O, et al. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation. 2003;75:1356-1360. (Pubitemid 36513048)
18. Teng R, Gavrilova O, Suzuki N, et al. Disrupted erythropoietin signalling promotes obesity and alters hypothalamus proopiomelanocortin production. Nat Commun. 2011;2:520.
19. Katz O, Stuible M, Golishevski N, et al. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol. 2010;205:87-95.
20. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med. 2010;207:2831-2842.
21. Mikolás E, Cseh J, Pap M, et al. Effects of erythropoietin on glucose metabolism. Horm Metab Res. 2012;44:279-285.
22. Allegra V, Martimbianco L, Vasile A. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant. 1997;12:924-932. (Pubitemid 27216312)
23. Borissova AM, Djambazova A, Todorov K, Dakovska L, Tankova T, Kirilov G. Effect of erythropoietin on the metabolic state and peripheral insulin sensitivity in diabetic patients on haemodialysis. Nephrol Dial Transplant. 1993;8:93.
24. Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol. 1996;16:304-308. (Pubitemid 26143579)
25. Pan Y, Shu JL, Gu HF, et al. Erythropoietin improves insulin resistance via the regulation of its receptor-mediated signaling pathways in 3T3L1 adipocytes. Mol Cell Endocrinol. 2013;367(1-2):116-123.
26. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci. 2006; 26:1269-1274. (Pubitemid 43237059)
27. Hausman DB, Park HJ, Hausman GJ. Isolation and culture of preadipocytes from rodent white adipose tissue. In: Yang K, ed. Adipose Tissue Protocols. 2nd ed. Totowa, NJ: Humana Press; 2008:201-219.
28. Miller CP, Liu ZY, Noguchi CT, Wojchowski DM. A minimal cytoplasmic subdomain of the erythropoietin receptor mediates erythroid and megakaryocytic cell development. Blood. 1999;94:3381-3387. (Pubitemid 29536132)
29. Ogilvie M, Yu X, Nicolas-Metral V, et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem. 2000;275:39754-39761. (Pubitemid 32059005)
30. Hamed S, Egozi D, Kruchevsky D, Teot L, Gilhar A, Ullmann Y. Erythropoietin improves the survival of fat tissue after its transplantation in nude mice. PLoS One. 2010;5:e13986.
31. Shi SY, Martin RG, Duncan RE, et al. Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance. J Biol Chem. 2012;287:10277-10288.
32. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-1830. (Pubitemid 38063705)
33. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796-1808. (Pubitemid 38063703)
34. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409. (Pubitemid 28232084)
35. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000;97:10526-10531.
36. Kaptanoglu E, Solaroglu I, Okutan O, Surucu HS, Akbiyik F, Beskonakli E. Erythropoietin exerts neuroprotection after acute spinal cord injury in rats: effect on lipid peroxidation and early ultrastructural findings. Neurosurg Rev. 2004;27:113-120. (Pubitemid 38374415)
37. Savino C, Pedotti R, Baggi F, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol. 2006; 172:27-37. (Pubitemid 43279681)
38. Grunfeld JF, Barhum Y, Blondheim N, Rabey JM, Melamed E, Offen D. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol. 2007;204:260-263. (Pubitemid 46350729)
39. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA. 2003;100: 11612-11617. (Pubitemid 37205984)
40. Parsa CJ, Kim J, Riel RU, et al. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem. 2004;279:20655-20662. (Pubitemid 38656460)
41. van der Meer P, Lipsic E, et al. Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail. 2004;6:853-859. (Pubitemid 39536300)
42. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J. 2004;18:1031-103343.
43. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation. 2004;110:1006-1012. (Pubitemid 39128626)
44. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990;87:5978-5982.
45. Hojman P, Brolin C, Gissel H. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One. 2009;4:e5894.
46. Suzuki N, Ohneda O, Takahashi S, et al. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002;100:2279-2288.
47. Sirén AL, Knerlich F, Poser W, Gleiter CH, Brück W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001;101:271-276. (Pubitemid 32219761)
48. Spandou E, Papoutsopoulou S, Soubasi V, et al. Hypoxia-ischemia affects erythropoietin and erythropoietin receptor expression pattern in the neonatal rat brain. Brain Res. 2004;1021:167-172. (Pubitemid 39165793)
49. Rupnick MA, Panigrahy D, Dallabrida SM, et al. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA. 2002;99:10730-10735.
50. Fukumura D, Ushiyama A, Duda DG, et al. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res. 2003;93:e88-e97.
51. Bråkenhielm E, Cao R, Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res. 2004;94:1579-1588. (Pubitemid 38856965)
52. Tam J, Duda DG, Perentes JY, Quadri RS, Fukumura D, Jain RK. Blockade of VEGFR2 and not VEGFR1 can limit diet-induced fat tissue expansion: role of local versus bone marrow-derived endothelial cells. PLoS One. 2009;4:e4974.
53. Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-2636. (Pubitemid 29181195)
54. Jaquet K, Krause K, Tawakol-Khodai M, Geidel S, Kuck KH. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002;64:326-333.
55. Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198:971-975. (Pubitemid 37152934)